ClinicalTrials.gov
ClinicalTrials.gov Menu

Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00500695
Recruitment Status : Completed
First Posted : July 13, 2007
Last Update Posted : July 18, 2017
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Marc L. Steinberg, Ph.D., Rutgers, The State University of New Jersey

Brief Summary:
This project will assess the utility of a brief motivational intervention to engage smokers with schizophrenia in treatment for tobacco dependence treatment. It is hypothesized that a brief motivational intervention will be more effective in engaging smokers with schizophrenia to tobacco dependence treatment than an educational intervention. The educational intervention will increase the likelihood to reducing cigarette intake and/or attending tobacco dependence treatment by teaching subjects about the negative effects of smoking and the success of tobacco dependence treatment. The motivational intervention will increase the likelihood to reducing cigarette intake and/or attending tobacco dependence treatment by increasing subjects' motivation to change by presenting objective and personalized information regarding their smoking behaviors in a non-judgmental and supportive manner.

Condition or disease Intervention/treatment Phase
Schizophrenia Schizoaffective Disorder Behavioral: Motivational Interviewing Behavioral: Psychoeducation Phase 1

Detailed Description:
See Brief Summary above.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 98 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness
Study Start Date : May 2006
Actual Primary Completion Date : October 2013
Actual Study Completion Date : October 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Motivational Interviewing
Motivational Interviewing
Behavioral: Motivational Interviewing
Motivational Interviewing

Active Comparator: Psychoeducation
Psychoeducation
Behavioral: Psychoeducation
Psychoeducation




Primary Outcome Measures :
  1. Attendance at first smoking cessation session [ Time Frame: one month ]

Secondary Outcome Measures :
  1. Cigarettes per day [ Time Frame: 1-Month Follow Up ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Current smokers must be over the age of 18,
  • Must have a diagnosis of schizophrenia or schizoaffective disorder
  • Must smoke at least 10 cigarettes per day
  • Must be capable of giving informed consent as measured by Folstein Mini Mental Status Exam of at least 22

Exclusion Criteria:

•Those unable to give informed consent.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00500695


Locations
United States, New Jersey
UMDNJ- Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08901
Sponsors and Collaborators
Rutgers, The State University of New Jersey
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Marc L. Steinberg, PH.D. Rutgers, The State University of New Jersey

Responsible Party: Marc L. Steinberg, Ph.D., Associate Professor, Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier: NCT00500695     History of Changes
Other Study ID Numbers: 220045018
K23DA018203 ( U.S. NIH Grant/Contract )
First Posted: July 13, 2007    Key Record Dates
Last Update Posted: July 18, 2017
Last Verified: July 2017

Additional relevant MeSH terms:
Schizophrenia
Psychotic Disorders
Mental Disorders
Schizophrenia Spectrum and Other Psychotic Disorders